# RetiSpec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/retispec

- Industry: Medical Devices & Equipment
- Headquarters: Toronto, Canada
- Website: www.retispec.com
- Total disclosed funding: $10M
- Latest round: Series A (Jul 21, 2024)
- Investors on record: 7

## About

Founded in 2016 by Eliav Shaked (CEO) and Roy Kirshon (COO), and based in Toronto, Canada, RetiSpec Inc. operates as a research medical imaging company that develops tools for the early detection of biomarkers of Alzheimer's disease in the eye. In July 2024, RetiSpec Inc. raised 10 million USD in series A funding led by iGan Partners, with participation from Centre for Aging + Brain Health Innovation, Eli Lilly and Company, Gentex Corporation, Verge HealthTech, University of Minnesota, and Topcon Healthcare.

The company employs AI-driven retinal imaging that uses data-rich retinal images captured with existing retinal imaging cameras to provide early and accurate diagnosis of neurodegenerative disease markers using eye examinations. RetiSpec's non-invasive, AI-based solution provides detailed analysis for using hyperspectral imaging to detect Alzheimer's disease.

## Funding rounds

- Series A, Jul 21, 2024, $10M — iGan Partners, Gentex Corporation, University of Minnesota, Verge HealthTech, Lilly, Centre for Aging + Brain Health Innovation, Topcon Healthcare

## Investors

- iGan Partners (https://capitalatlas.ai/funds/igan-partners) — Series A
- Gentex Corporation — Series A
- University of Minnesota — Series A
- Verge HealthTech (https://capitalatlas.ai/funds/verge-healthtech) — Series A
- Lilly — Series A
- Centre for Aging + Brain Health Innovation — Series A
- Topcon Healthcare — Series A